Condition: Asthma · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the superiority in terms of efficacy and evaluate the safety of QMF149 (indacaterol (acetate) / mometasone (furoate)) compared to budesonide in children from 6 to less than 12 years of age with asthma. * The study duration will be up to 37 weeks including an investigational treatment duration of 12 weeks and a comparator treatment duration of 12 weeks. * The visit frequency will be 3 weeks for screening, run-in and wash-out period, 6 weeks interval for visits during each treatment period, 30 days for safety follow-up.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | CABA, Buenos Aires, Argentina | Recruiting |
| Novartis Investigative Site | CABA, Buenos Aires, Argentina | Recruiting |
| Novartis Investigative Site | CABA, Buenos Aires, Argentina | Recruiting |
| Novartis Investigative Site | Mendoza, Mendoza Province, Argentina | Recruiting |
| Novartis Investigative Site | Rosario, Santa Fe Province, Argentina | Recruiting |
| Novartis Investigative Site | Rosario, Santa Fe Province, Argentina | Recruiting |
| Novartis Investigative Site | Graz, Austria | Withdrawn |
| Novartis Investigative Site | Salzburg, Austria | Withdrawn |
| Novartis Investigative Site | Sankt Pölten, Austria | Withdrawn |
| Novartis Investigative Site | Sorocaba, São Paulo, Brazil | Recruiting |
| Novartis Investigative Site | Rousse, Bulgaria | Recruiting |
| Novartis Investigative Site | Sevlievo, Bulgaria | Recruiting |
+ 51 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05562466